Ex­clu­sive: An­dreessen Horowitz-backed start­up is us­ing AI to de­sign lipid nanopar­ti­cles that go be­yond the liv­er

One of the biggest chal­lenges fac­ing ge­net­ic med­i­cines is get­ting them to the right part of the body. Lit­tle balls of fat called lipid nanopar­ti­cles used to car­ry mR­NA can be in­ject­ed in­to the arm for vac­cines or in­fused in­to the blood to shut­tle ge­net­ic med­i­cines to the liv­er. But de­liv­er­ing the mol­e­cules to oth­er cells or or­gans re­mains a chal­lenge.

A new start­up called Mana.bio hopes to change that, End­points News has learned. Based in Tel Aviv, Is­rael, Mana.bio has raised $19.5 mil­lion in seed fi­nanc­ing from An­dreessen Horowitz Bio + Health (a16z), Base4 Cap­i­tal, NFX, Li­on­Bird and Tech­nion — Is­rael In­sti­tute of Tech­nol­o­gy.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER